Generic Edarbi Availability
Last updated on Sep 10, 2026.
Edarbi is a brand name of azilsartan medoxomil, approved by the FDA in the following formulation:
| Manufacturer | Approval date | Strengths [RLD] [AB] |
|---|---|---|
| AZURITY | February 25, 2011 |
|
Has a generic version of Edarbi been approved?
Yes, the FDA has approved a generic version of Edarbi. However, FDA approval doesn't guarantee the generic will be available in pharmacies. Drug patents or exclusivity rights that are still active can legally prevent manufacturers from selling the generic even after FDA approval.
| Manufacturer | Approval date | Strengths [AB] |
|---|---|---|
| LUPIN | July 20, 2022 |
|
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Edarbi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Generic Edarbi prices
The pricing data below reflects current availability in the marketplace and indicates that the medication is available for purchase.
| Drug | Form | Strength | Drugs.com Price Guide |
|---|---|---|---|
| Azilsartan Medoxomil | oral tablet | 40 mg | from $203.67 for 30 |
| Azilsartan Medoxomil | oral tablet | 80 mg | from $220.7 for 30 |
|
See all prices for: Azilsartan Medoxomil |
|||
Generic Edarbi Marketing Start Dates
Marketing start dates are when each generic version first became available from each manufacturer.
Patent protection
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development. These patents may include claims related to the drug's formulation, manufacturing process, or other aspects.
| Patent Title | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
|---|---|
| Patent Number | 9,066,936 |
| Issue Date | June 30, 2015 |
| Inventor | Yoneyama Shuji & Tanoue Yutaka |
| Current Assignee | Takeda Pharmaceutical Company Limited |
| Patent Description |
The present invention provides a solid pharmaceutical composition containing compound (I) having an angiotensin II receptor antagonistic action and defined in the specification and a pH control agent, which composition is superior in the stability...
The present invention provides a solid pharmaceutical composition containing compound (I) having an angiotensin II receptor antagonistic action and defined in the specification and a pH control agent, which composition is superior in the stability and dissolution property of compound (I).
|
| Patent Expiry Dates |
March 26, 2028
Drug Product: Yes |
More about Edarbi (azilsartan medoxomil)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (46)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: angiotensin receptor blockers
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
